The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer’s disease

Ishikawa, Ichiro; Shinno, Hideto; Ando, Nobuo; Mori, Takahiro; Nakamura, Yu

doi:10.1017/neu.2015.61

Cited by 19 publications

(22 citation statements)

References 45 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The contribution of medications administered for the neurodegenerative condition itself should also be considered, especially with respect to timing and dose. For example, donepezil and memantine administered for Alzheimer's have been shown to improve sleep quality overall [67,68] but donepezil may cause sleep disruption if taken late in the day [69]; modification of timing may therefore bring benefit. Likewise, dopamine agonists improve sleep quality and daytime functioning in Parkinson's [70,71] but carry a dose-related risk of excessive daytime somnolence and sleep attacks; therefore, dosing should be reviewed in the setting of sleep dysfunction.…”

Section: Influence Of Medications For Neurodegenerative Conditionsmentioning

confidence: 99%

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

2021

View full text Add to dashboard Cite

Sleep dysfunction is highly prevalent across the spectrum of neurodegenerative conditions and is a key determinant of quality of life for both patients and their families. Mounting recent evidence also suggests that such dysfunction exacerbates cognitive and affective clinical features of neurodegeneration, as well as disease progression through acceleration of pathogenic processes. Effective assessment and treatment of sleep dysfunction in neurodegeneration is therefore of paramount importance; yet robust therapeutic guidelines are lacking, owing in part to a historical paucity of effective treatments and trials. Here, we review the common sleep abnormalities evident in neurodegenerative disease states and evaluate the latest evidence for traditional and emerging interventions, both pharmacological and nonpharmacological. Interventions considered include conservative measures, targeted treatments of specific clinical sleep pathologies, established sedating and alerting agents, melatonin, and orexin antagonists, as well as bright light therapy, behavioral measures, and slow-wave sleep augmentation techniques. We conclude by providing a suggested framework for treatment based on contemporary evidence and highlight areas that may emerge as major therapeutic advances in the near future.

show abstract

Section: Influence Of Medications For Neurodegenerative Conditionsmentioning

confidence: 99%

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

2021

View full text Add to dashboard Cite

show abstract

“…They have concluded that memantine was effective in reducing fragmented sleep. 13 Ishida et al hypothesized that memantine may be useful for the treatment of excessive daytime sleepiness. They studied the effect of memantine on excessive sleepiness after 6 h of sleep deprivation in adult rats.…”

Section: Resultsmentioning

confidence: 99%

Potentiation of general anaesthetic activity of ketamine by memantine

Umamageswari

Vasanthan

Karthikeyan

2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The study was done with the objective to evaluate synergistic activity of ketamine induced general anesthesia by memantine in wistar albino rats.Methods: The wistar albino rats of either sex were divided into four groups of five animals. Group 1 received ketamine 40 mg/kg, group 2 received ketamine 80 mg/kg, group 3 received ketamine 40 mg/kg along with memantine 10 mg/kg and group 4 received 80 mg of ketamine along with memantine 10 mg/kg to evaluate the synergistic activity of ketamine induced general anesthesia by memantine. The sleep latency time and duration of sleep were measured in all the groups.Results: The sleep latency time of group 4 is significantly decreased (p<0.001) compared to all other groups. The duration of sleep of group 4 is significantly increased (p<0.001) compared to group 1 and group 3, but less than that of group 1.Conclusions: Memantine possess synergistic activity of ketamine induced general anaesthesia.

show abstract

“…Glutamatergic signaling, which plays an integrated role in the regulation of sleep stages and arousal (Shi and Yu, 2013), also deteriorates in AD patients. Memantine, a moderate affinity N-methyl-Daspartate receptor antagonist, has been shown to increase total time spent sleeping in AD patients treated with 20 mg/day for 4 weeks (Ishikawa et al, 2016). However, due to the nature of receptor desensitization and transient efficacy of this drug, it is not a good long-term pharmacological candidate to break the altered sleep architecture and inflammation cycle discussed here.…”

Section: Alzheimer's Disease -Inflammation and Sleep Pathologymentioning

confidence: 93%

The Bidirectional Relationship Between Sleep and Inflammation Links Traumatic Brain Injury and Alzheimer’s Disease

et al. 2020

View full text Add to dashboard Cite

Traumatic brain injury (TBI) and Alzheimer's disease (AD) are diseases during which the fine-tuned autoregulation of the brain is lost. Despite the stark contrast in their causal mechanisms, both TBI and AD are conditions which elicit a neuroinflammatory response that is coupled with physical, cognitive, and affective symptoms. One commonly reported symptom in both TBI and AD patients is disturbed sleep. Sleep is regulated by circadian and homeostatic processes such that pathological inflammation may disrupt the chemical signaling required to maintain a healthy sleep profile. In this way, immune system activation can influence sleep physiology. Conversely, sleep disturbances can exacerbate symptoms or increase the risk of inflammatory/neurodegenerative diseases. Both TBI and AD are worsened by a chronic pro-inflammatory microenvironment which exacerbates symptoms and worsens clinical outcome. Herein, a positive feedback loop of chronic inflammation and sleep disturbances is initiated. In this review, the bidirectional relationship between sleep disturbances and inflammation is discussed, where chronic inflammation associated with TBI and AD can lead to sleep disturbances and exacerbated neuropathology. The role of microglia and cytokines in sleep disturbances associated with these diseases is highlighted. The proposed sleep and inflammation-mediated link between TBI and AD presents an opportunity for a multifaceted approach to clinical intervention.

show abstract

The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer’s disease

Abstract: Memantine was effective for reducing fragmented sleep and improving BPSD, and was well tolerated.

Cited by 19 publications

References 45 publications

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

Potentiation of general anaesthetic activity of ketamine by memantine

The Bidirectional Relationship Between Sleep and Inflammation Links Traumatic Brain Injury and Alzheimer’s Disease

Contact Info

Product

Resources

About